Dose-by-dose virological and hematological responses to intravenous immunoglobulin in an immunocompromised patient with persistent parvovirus B19 infection

Journal of Medical Virology

Volumn 79, Issue 9, 2007, Pages 1401-1405

  Tang, Julian W ^a   Lau, June S M ^b   Wong, Stephanie Y N ^b   Cheung, Jo L K ^a   Chan, C H ^b   Wong, K F ^b   Wong, Ann ^c   Chan, Paul K S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^c DEPARTMENT OF HEALTH   (Hong Kong)

Author keywords

Monitoring; Pancytopaenia; Pure red cell aplasia; Response

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE; VIRUS DNA;

ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CASE REPORT; DOSE RESPONSE; ERYTHROCYTE APLASIA; HUMAN; IMMUNE DEFICIENCY; IMMUNOTHERAPY; MALE; MANTLE CELL LYMPHOMA; NONHUMAN; PANCYTOPENIA; PARVOVIRUS; PERSISTENT INFECTION; REPEATED DRUG DOSE;

ADULT; COMBINED MODALITY THERAPY; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULINS, INTRAVENOUS; LYMPHOMA, MANTLE-CELL; MALE; PANCYTOPENIA; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION;

PARVOVIRUS;

EID: 34547101202     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20870     Document Type: Article

References (25)

1. Azzi A, Fanci R, Ciappi S, Zakrzewska K, Bosi A. 1993. Human parvovirus B19 infection in bone marrow transplantation patients. Am J Hematol 44:207-209.
2. Blumel J, Schmidt I, Effenberger W, Seitz H, Willkommen H, Brackmann HH, Lower J, Eis-Hubinger AM. 2002. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion 42:1473-1481.
3. Castelli R, Vismara A, Pavia G, Dagani R, Porro T. 2002. Relapsing pure red cell aplasia associated with B-cell chronic lymphocytic leukemia successfully treated by intravenous immunoglobulin concentrate. Ann Ital Med Int 17:47-50.
4. Chisaka H, Morita E, Yaegashi N, Sugamura K. 2003. Parvovirus B19 and the pathogenesis of anaemia. Rev Med Virol 13:347-359.
5. Choi SH, Chang SP, Won JC, Lee JS, Chi HS, Yang WS, Park SK. 2002. A case of persistent anemia in a renal transplant recipient: Association with parvovirus B19 infection. Scand J Infect Dis 34:71-75.
6. Darabi K, Abdel-Wahab O, Dzik WH. 2006. Current usage of intravenous immune globulin and the rationale behind it: The Massachusetts General Hospital data and a review of the literature. Transfusion 46:741-753.
7. Eid AJ, Brown RA, Patel R, Razonable RR. 2006. Parvovirus B19 infection after transplantation: A review of 98 cases. Clin Infect Dis 43:40-48.
8. Gallinella G, Moretti E, Nardi G, Zuffi E, Bonvicini F, Bucci E, Musiani M, Zerbini M. 2002. Analysis of B19 virus contamination in plasma pools for manufacturing, by using a competitive polymerase chain reaction assay. Vox Sang 83:324-331.
9. Hayakawa F, Imada K, Towatari M, Saito H. 2002. Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Br J Haematol 118:1187-1189.
10. Heegaard ED, Brown KE. 2002. Human parvovirus B19. Clin Microbiol Rev 15:485-505.
11. Hung CC, Lee KL, Chen MY. 2001. Increase in B19 viral load prior to relapse of anaemia in an AIDS patient with persistent B19 infection. J Infect 43:150-152.
12. Isobe Y, Sugimoto K, Shiraki Y, Nishitani M, Koike K, Oshimi K. 2004. Successful high-titer immunoglobulin therapy for persistent parvovirus B19 infection in a lymphoma patient treated with rituximab-combined chemotherapy. Am J Hematol 77:370-373.
13. Kaptan K, Beyan C, Ural AU, Ustun C, Cetin T, Avcu F, Kubar A, Alis M, Yalcin A. 2001. Successful treatment of severe aplastic anemia associated with human parvovirus B19 and Epstein-Barr virus in a healthy subject with allo-BMT. Am J Hematol 67:252-255.
14. Keller MA, Stiehm ER. 2000. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 13:602-614.
15. Lui SL, Luk WK, Cheung CY, Chan TM, Lai KN, Peiris JS. 2001. Nosocomial outbreak of parvovirus B19 infection in a renal transplant unit. Transplantation 71:59-64.
16. Moudgil A, Shidban H, Nast CC, Bagga A, Aswad S, Graham SL, Mendez R, Jordan SC. 1997. Parvovirus B19 infection-related complications in renal transplant recipients: Treatment with intravenous immunoglobulin. Transplantation 64:1847-1850.
17. Mouthon L, Guillevin L, Tellier Z. 2005. Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia. Autoimmun Rev 4:264-269.
18. Ramratnam B, Gollerkeri A, Schiffman FJ, Rintels P, Flanigan TP. 1995. Management of persistent B19 parvovirus infection in AIDS. Br J Haematol 91:90-92.
19. Sharma VR, Fleming DR, Slone SP. 2000. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 96:1184-1186.
20. Song KW, Mollee P, Patterson B, Brien W, Crump M. 2002. Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. Br J Haematol 119:125-127.
21. Weimer T, Streichert S, Watson C, Groner A. 2001. High-titer screening PCR: A successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation. Transfusion 41:1500-1504.
22. Wicki J, Samii K, Cassinotti P, Voegeli J, Rochat T, Beris P. 1997. Parvovirus [correction of Parovirus] B19-induced red cell aplasia in solid-organ transplant recipients. Two case reports and review of the literature. Hematol Cell Ther 39:199-204.
23. Wong KF, Chu YC, Lim WWL. 1993. Parvovirus-induced red cell aplasia - A diagnostic engima. Clin Lab Haematol 15:305-308.
24. Wong TY, Chan PK, Leung CB, Szeto CC, Tam JS, Li PK. 1999. Parvovirus B19 infection causing red cell aplasia in renal transplantation on tacrolimus. Am J Kidney Dis 34:1132-1136.
25. Yap PL. 1994. Does intravenous immune globulin have a role in HIV-infected patients? Clin Exp Immunol 97:59-67.